FDA OKs Istradefylline for Parkinson’s Disease ‘Off’ Episodes

Share this post

Oral istradefylline (Nourianz) reduces "off" episodes when added to levodopa/carbidopa in patients with Parkinson’s disease.
FDA Approvals

This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.

Share this post

Be the first to comment

Leave a Reply